ID: 206	RANK: 100	SCORE: 18.366320
<DOC>
<DOCNO> WSJ870803-0030 </DOCNO>
<HL> Business Brief:
Biocraft Laboratories Inc.</HL>
<DD> 08/03/87</DD>
<SO> WALL STREET JOURNAL (J)</SO>
<IN> BCL </IN>
<TEXT>
   Biocraft Laboratories Inc., Elmwood Park, N.J., said it expects to post at least a fivefold increase in net income, to an indicated $3.5 million, or 30 cents a share, for its first quarter ended June 30. 
In the year-earlier period, the maker of generic drugs earned $700,000, or six cents a share. 
Sales are expected to double, to an indicated $17 million. 
The company cited strength in its core penicillin business and sales of cephalosporins, a generic version of an Eli Lilly &amp; Co. antibiotic, which Biocraft began marketing this year after Eli Lilly's patent ran out. 
In New York Stock Exchange composite trading Friday, Biocraft shares rose $1.375, to close at $20.50. 

   (See: "Corrections &amp; Amplifications: Biocraft Laboratories Inc." -- WSJ August 4, 1987) 

</TEXT>
</DOC>
